DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic Effects
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic Effects
Authors
Keywords
-
Journal
Neuroscience Bulletin
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-12-06
DOI
10.1007/s12264-019-00446-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
- (2019) Emelia J. Benjamin et al. CIRCULATION
- Apoptotic cell death regulation in neurons
- (2019) Emilie Hollville et al. FEBS Journal
- The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors
- (2018) Vladimer Darsalia et al. Cardiovascular Diabetology
- Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke
- (2018) Yan-Rong Li et al. Cardiovascular Diabetology
- The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway
- (2018) Fausto Chiazza et al. Cardiovascular Diabetology
- Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model
- (2018) Liping Zhang et al. NEUROPEPTIDES
- Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential
- (2018) Vladimer Darsalia et al. NEUROPHARMACOLOGY
- Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models
- (2018) Christian Hölscher NEUROPHARMACOLOGY
- Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in Type 2 diabetes
- (2016) Trevor Hardigan et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
- (2016) Dilan Athauda et al. DRUG DISCOVERY TODAY
- An update on DPP-4 inhibitors in the management of type 2 diabetes
- (2016) Avivit Cahn et al. EXPERT OPINION ON EMERGING DRUGS
- The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia
- (2016) Fangzhe Chen et al. Journal of Neuroinflammation
- Diabetes-mediated middle cerebral artery remodeling is restored by linagliptin: Interaction with the vascular smooth muscle cell endothelin system
- (2016) Abdul Yasir et al. LIFE SCIENCES
- Activation of GLP-1 Receptor Enhances Neuronal Base Excision Repair via PI3K-AKT-Induced Expression of Apurinic/Apyrimidinic Endonuclease 1
- (2016) Jenq-Lin Yang et al. Theranostics
- Cell Death Signaling
- (2015) Douglas R. Green et al. Cold Spring Harbor Perspectives in Biology
- Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism
- (2014) Nadia M. Krasner et al. PLoS One
- Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice
- (2013) Dong Yang et al. BRAIN RESEARCH
- The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant?
- (2013) Stefan Trapp et al. CURRENT OPINION IN PHARMACOLOGY
- Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes
- (2013) A. Ceriello et al. DIABETES CARE
- Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
- (2013) Baptist Gallwitz Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride
- (2012) V. Darsalia et al. DIABETES
- A novel stroke therapy of pharmacologically induced hypothermia after focal cerebral ischemia in mice
- (2012) Ko-Eun Choi et al. FASEB JOURNAL
- Neuroprotective actions of Glucagon-like peptide-1 in differentiated human neuroprogenitor cells
- (2012) Kalpana Velmurugan et al. JOURNAL OF NEUROCHEMISTRY
- Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats
- (2011) Wei Jing Liu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Anti-Inflammatory Properties of Exenatide in Human Pancreatic Islets
- (2011) S. R. Cechin et al. CELL TRANSPLANTATION
- Forecasting the Future of Cardiovascular Disease in the United States
- (2011) Paul A. Heidenreich et al. CIRCULATION
- Neuroprotective properties of GLP-1: theoretical and practical applications
- (2011) Jens Juul Holst et al. CURRENT MEDICAL RESEARCH AND OPINION
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
- (2011) R. Kodera et al. DIABETOLOGIA
- A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism
- (2009) Remy Burcelin et al. CURRENT OPINION IN PHARMACOLOGY
- Control of mitochondrial apoptosis by the Bcl-2 family
- (2009) J. K. Brunelle et al. JOURNAL OF CELL SCIENCE
- Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives
- (2009) Dirk Sander et al. JOURNAL OF NEUROLOGY
- Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-β peptide (1–42)
- (2008) Zhenxia Qin et al. NEUROSCIENCE LETTERS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started